WuXi XDC Cayman Inc. Stock

Equities

2268

KYG9808A1058

Pharmaceuticals

End-of-day quote Hong Kong S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
20.5 USD +2.50% Intraday chart for WuXi XDC Cayman Inc. +18.09% -35.94%
Sales 2023 2.12B 293M Sales 2024 * 3.16B 436M Capitalization 22.36B 3.09B
Net income 2023 284M 39.19M Net income 2024 * 577M 79.63M EV / Sales 2023 16.1 x
Net cash position 2023 * 3.52B 486M Net cash position 2024 * 3.37B 465M EV / Sales 2024 * 6.02 x
P/E ratio 2023
112 x
P/E ratio 2024 *
38.8 x
Employees 1,178
Yield 2023 *
-
Yield 2024 *
-
Free-Float 15.77%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.50%
1 week+18.09%
Current month+12.02%
1 month+20.31%
3 months-18.65%
Current year-35.94%
More quotes
1 week
17.26
Extreme 17.26
20.90
1 month
16.50
Extreme 16.5
20.90
Current year
12.08
Extreme 12.08
33.10
1 year
12.08
Extreme 12.08
34.00
3 years
12.08
Extreme 12.08
34.00
5 years
12.08
Extreme 12.08
34.00
10 years
12.08
Extreme 12.08
34.00
More quotes
Date Price Change Volume
24-04-26 20.5 +2.50% 2,757,509
24-04-25 20 +5.37% 1,635,534
24-04-24 18.98 -1.86% 1,993,813
24-04-23 19.34 +3.20% 4,171,684
24-04-22 18.74 +7.95% 1,836,981

End-of-day quote Hong Kong S.E., April 25, 2024

More quotes
WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The Company conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The Company conducts its business in domestic and foreign markets.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
18.98 CNY
Average target price
28.68 CNY
Spread / Average Target
+51.12%
Consensus

Quarterly revenue - Rate of surprise